Latest Venous thrombosis Stories
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
The Firm is representing plaintiffs in Xarelto lawsuits who allegedly suffered uncontrollable internal bleeding and other complications related to its use. New
Findings presented at American Heart Association's Scientific Sessions add to growing body of data supporting safety and effectiveness of PRADAXA RIDGEFIELD, Conn., Nov.
The Firm is representing individuals in Xarelto lawsuits that allege use of the blood-thinning medication caused serious complications, including uncontrollable internal bleeding. New
The Firm is evaluating Xarelto lawsuits on behalf of patients who experienced uncontrollable internal bleeding, strokes, deep vein thrombosis, pulmonary embolism, or other complications allegedly
- Poster on research about investigational, specific antidote for PRADAXA also to be presented RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Xarelto Page Launched to Monitor Lawsuits Being Filed on Behalf of Patients Who Allege the Blood Thinner Causes Severe Internal Bleeding and Uncontrollable Bleeding New
- Committee votes 9 to 1 to recommend approval of once-daily SAVAYSA for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF) TOKYO,
The Firm is evaluating Xarelto lawsuits on behalf of individuals who experienced uncontrollable internal bleeding, blood clots, and other serious complications, allegedly due to their use of the
- The governor of a province or people.